Heyman Richard A. sold $84K of ORIC
Heyman Richard A. sold 7,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.02 on 2026-07-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity, but because it is explicitly under a pre-arranged 10b5-1 plan, it is less likely to represent new private information.
Market read
Traders may note the sale for sentiment/positioning, but it is unlikely to drive fundamentals.
What to watch
The article does not disclose whether other insiders sold/bought around the same time, nor does it provide context for the director’s liquidity needs.
Background
This is an SEC Form 4 insider transaction for Oric Pharmaceuticals, Inc. (ORIC).
Ticker impact
Oric Pharmaceuticals director Heyman Richard A. sold 7,000 shares on 2026-07-24 for about $84.1K under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to typical company market caps.
Market effects
No clear sector read-through from a single, modest 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative sentiment input.
Key entities
- issuerOric Pharmaceuticals, Inc.
Company whose director executed an open-market sale under a 10b5-1 plan.
- insiderHeyman Richard A.
Director who sold 7,000 shares at $12.0200/share.